Making Tomorrow’s
Cancer Treatment Better
We are Isofol
Isofol is a publicly listed biotech company dedicated to developing arfolitixorin, a next-generation folate-based drug candidate designed to enhance the efficacy of standard treatments for patients with severe cancer.
Our goal is s to have a central impact on tomorrow’s cancer care – helping more patients respond better to their treatment, improve their prognosis, and gain more time with life.
Isofol’s shares are traded on Nasdaq Stockholm.
Latest press releases
2025-11-14
Interview with Charité – Universitätsmedizin Berlin
Watch the interview with Prof. Sebastian Stintzing who is the principal coordinating investigator in Isofol’s on-going phase Ib/II study.
2025-11-14
Investor Meeting
On November 13 Isofol invited to an investor meeting to provide an update on the company’s ongoing clinical study with the drug candidate arfolitixorin.
2025-10-08
CEO interview
Isofol’s CEO, Petter Segelman Lindqvist, was interviewed by Dagens Industri Investor Relations for an update on the company.
For investors
Upcoming Events
- January 21, 2026 - January 21, 2026
Redeye Fight Cancer Day, Stockholm
Isofol attending during this day with a short presentation followed by a live Q&A session with Redeye’s analysts. - February 18, 2026 - February 18, 2026
Year-end report 2025 - May 19, 2026 - May 19, 2026
Interim Report January-March 2026
Latest reports and presentations
